Opinion|Videos|May 2, 2024
Physician Awareness of Cognitive Dysfunction in Schizophrenia
Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, discuss awareness among physicians of the concept of cognitive impairment associated with schizophrenia and detail unmet needs, including the lack of approved therapies, measurement tools, and access to cognitive remediation.
Advertisement
Episodes in this series
Advertisement
Related to this article
Review the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.
Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.
Explore how OCD and schizophrenia overlap, complicating diagnosis and care, and learn spectrum-based strategies and treatment pitfalls for managing schizo-obsessive symptoms.
How estrogen dips during menstruation, pregnancy, postpartum, and menopause can trigger schizophrenia relapse, and what it means for antipsychotic dosing.
Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Scams: What Psychiatrists Need to Know
2
FDA Shelves Fast-Track Drug Review Initiative
3
Reviewing Roluperidone as Treatment for Negative Symptoms in Schizophrenia
4
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
5